FDAsafety guidance66% confidence
Investigational New Drug (IND) Application
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Eli Lilly; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Get to know the investigational new drug application (IND). This includes the types, laws and regulations, and emergency use of INDs.
Supporting Context
- Therapeutic area
- Neurology · CGRP Inhibitor
- Sub-indication
- General
Related signal: FDA Accepts Supplemental Application for Emgality (Galcanezumab)